The pharmaceutical company Sobi updates its outlook for 2016 just three days after the financial statements in which the company announced forecasts.
The reason is the positive recommendation by the Scientific Committee for Medicinal Products (CHMP) gave the Alprolix on Friday and Sobi now expect the European Commission may assign product marketing approval in second quarter in 2016.
According to a press release.
Sobi now expects revenue for the full year will be in the range 4800-5000 millions. Total income includes a one-time credit for Elocta of 300 to 325 million and Alprolix of 300 to 325 million, which would not affect cash. Gross margin is expected to be in the range of 68-70 percent.
EBITA for the full year was expected to be in the range of 1200-1300 millions.
According SIX News / Inquiry Financials analyst survey before the financial statements were expected sales in the average amount to 4.94 billion kronor in 2016. EBITA analysts corps was expected to average land on 1.731 billion for in 2016.
the forecasts were left on Friday was revenue in the range of 4.3 to 4.5 billion, gross margin of 66- 68 percent and an EBITA profit in the range of 700-800 million.
the company will continue to invest in the launch of Elocta and Alprolix and will also be charged a cost of 250 to 300 million, equivalent to half of Biogen current development costs for the products. The costs will accrue Sobi while marketing authorization for the products transferred to Sobi, which is expected during the first quarter of 2016 Elocta and the second half of 2016 for Alprolix. These extra costs are included in the outlook.
No comments:
Post a Comment